New hope for deadly neuroendocrine cancers as experimental drug trial seeks to control tumors
NCT ID NCT04412629
Summary
This study is testing whether the drug cabozantinib can help control aggressive neuroendocrine tumors that have returned after initial treatment. Researchers will enroll 35 adults whose cancer has progressed despite previous therapies to see if cabozantinib shrinks tumors and extends survival. The trial focuses on patients with high-grade neuroendocrine neoplasms, which often spread quickly and have limited treatment options after initial therapy fails.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE NEUROENDOCRINE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.